Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H8O6 |
| Molecular Weight | 272.2097 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(O)C2=C(C=C1)C(=O)C3=C(O)C=CC(O)=C3C2=O
InChI
InChIKey=VBHKTXLEJZIDJF-UHFFFAOYSA-N
InChI=1S/C14H8O6/c15-6-3-4-7(16)11-10(6)12(18)5-1-2-8(17)13(19)9(5)14(11)20/h1-4,15-17,19H
| Molecular Formula | C14H8O6 |
| Molecular Weight | 272.2097 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Quinalizarin, a specific enzyme protein kinase CK2 inhibitor, affects the cell proliferation, migration, and apoptosis of different pathological and genetic types of human lung cancer cell lines. This can be reached via ROS mediated MAPK and STAT3 signaling pathways. Also was revealed, that quinalizarin could induce apoptosis in gastric cancer cells via MAPK and Akt signaling pathway.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The role of protein kinase CK2 in the regulation of the insulin production of pancreatic islets. | 2010-10-15 |
|
| Selective cloud point extraction and graphite furnace atomic absorption spectrometric determination of molybdenum (VI) ion in seawater samples. | 2009-09-30 |
|
| Preconcentration and separation of ultra-trace beryllium using quinalizarine-modified magnetic microparticles. | 2009-07-30 |
|
| Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. | 2009-07-15 |
|
| Rapid determination of aluminum by UV-vis diffuse reflectance spectroscopy with application of suitable adsorbents. | 2006-12-15 |
|
| Spectrophotometric microdetermination of nefopam, mebevrine and phenylpropanolamine hydrochloride in pharmaceutical formulations using alizarins. | 2004-07 |
|
| Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. | 2004-01-09 |
|
| Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin. | 2002-07-20 |
|
| Linkage and redox isomerism in ruthenium complexes of catecholate, semi-quinone, and o-acylphenolate ligands derived from tri- and tetrahydroxy-9,10-anthracenediones. | 2001-08-13 |
|
| Quinalizarin anchored on Amberlite XAD-2. A new matrix for solid-phase extraction of metal ions for flame atomic absorption spectrometric determination. | 2001-06 |
|
| Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. | 1998-09 |
|
| Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. | 1996-09-03 |
|
| Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase. | 1995-11-15 |
|
| Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. | 1994-09-01 |
|
| Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. | 1992-01 |
|
| Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. | 1991-03-01 |
Sample Use Guides
In Vitro Use Guide
Curator's Comment: Quinalizarin inhibited lung cancer A549, NCI H460 and NCI H23 cells proliferation and induced A549 cell cycle arrest at the G0/G1 phase. Quinalizarin induced apoptosis by upregulating the expression of B cell lymphoma 2 (Bcl 2) associated agonist of cell death, cleaved caspase 3 and cleaved poly (adenosine diphosphate ribose) polymerase, and downregulating the expression of Bcl 2.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:22:08 GMT 2025
by
admin
on
Mon Mar 31 21:22:08 GMT 2025
|
| Record UNII |
6D43C3LYSG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m9436
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | Merck Index | ||
|
4896
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
201-366-6
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
6D43C3LYSG
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
5004
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
DB08660
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
37495
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
DTXSID4052558
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
144046
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
QUINALIZARIN
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY | |||
|
81-61-8
Created by
admin on Mon Mar 31 21:22:08 GMT 2025 , Edited by admin on Mon Mar 31 21:22:08 GMT 2025
|
PRIMARY |